šŸ§¬Tidera Health
āš•ļø

Educational tool only. Does not confirm eligibility or provide medical advice. Always consult your physician before pursuing any trial.

OncologyICD-10: C67

Find Recruiting Clinical Trials for Bladder Cancer

Search NMIBC, MIBC, immunotherapy, antibody-drug conjugate, and FGFR-targeted bladder cancer trials.

šŸ” Search Bladder Cancer Trials ā†’

About Bladder Cancer

Bladder cancer is the 6th most common cancer in the United States, with approximately 83,000 new cases annually. The majority (75%) present as non-muscle-invasive bladder cancer (NMIBC), managed with TURBT and intravesical therapy (BCG, chemotherapy), but with high recurrence rates. Muscle-invasive bladder cancer (MIBC) requires radical cystectomy or aggressive bladder-sparing chemoradiation. Metastatic urothelial carcinoma has seen rapid therapeutic advances with checkpoint inhibitors, FGFR inhibitors (for FGFR3-mutant tumors), and antibody-drug conjugates (enfortumab vedotin, sacituzumab govitecan).

What Types of Bladder Cancer Clinical Trials Exist?

Bladder cancer trials span all disease stages. NMIBC trials test BCG-unresponsive disease treatments (nadofaragene, pembrolizumab intravesical), novel intravesical agents, and maintenance strategies. MIBC trials test neoadjuvant immunotherapy combinations before cystectomy. Metastatic urothelial carcinoma trials test new ADC combinations, FGFR inhibitor combinations (for FGFR3-altered tumors), checkpoint inhibitor doublets, and novel bispecific antibodies. FGFR3 mutation/fusion status, PD-L1 expression, and prior BCG or platinum exposure determine eligibility.

Find Recruiting Bladder Cancer Trials Near You

Enter your profile and we'll search ClinicalTrials.gov in real time ā€” matching trials to your age, location, and treatment history. Free, no account required.

Search Bladder Cancer Trials ā†’

Data from ClinicalTrials.gov Ā· Updated in real time Ā· Educational use only

Frequently Asked Questions

What clinical trials are available for bladder cancer?ā–¾
Recruiting bladder cancer trials include BCG-unresponsive NMIBC trials (nadofaragene firadenovec follow-on studies, pembrolizumab intravesical), neoadjuvant immunotherapy for MIBC, FGFR inhibitor combinations (for FGFR3-altered urothelial carcinoma), ADC combinations (enfortumab vedotin + pembrolizumab extension), bispecific antibodies, and bladder-sparing trimodality therapy protocols.
What is BCG-unresponsive bladder cancer and what trials target it?ā–¾
BCG-unresponsive NMIBC is defined as high-grade disease that persists or recurs within 6 months of adequate BCG therapy (at least 5 of 6 induction + at least 2 of 3 maintenance, or 2 induction courses). This population has historically faced radical cystectomy as the only option. Multiple novel intravesical agents ā€” nadofaragene, pembrolizumab, N-803 ā€” are approved or in late-stage trials for BCG-unresponsive disease.
How does FGFR status affect bladder cancer trial eligibility?ā–¾
FGFR3 mutations or fusions occur in approximately 15ā€“20% of metastatic urothelial carcinoma and are the biomarker for erdafitinib (FDA-approved FGFR inhibitor). FGFR3-targeted trials specifically require confirmed FGFR3 alterations on tumor molecular profiling. Next-generation FGFR inhibitors in clinical trials may have broader FGFR1ā€“4 coverage.

Related Conditions

Kidney CancerProstate CancerColorectal Cancer

Data source: All clinical trial information is sourced from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Tidera Health is an independent educational platform and is not affiliated with ClinicalTrials.gov or the National Library of Medicine. Always verify trial details directly with the research coordinator or your physician.